ArticleNature communications2022
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia.Chinese medical journal · 2026Article
- Paediatric blastic plasmacytoid dendritic cell neoplasm: a single-centre case series of 18 children and review of the literature.Annals of hematology · 2026Review
- Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature.Frontiers in immunology · 2026Review
- Case Report: Blastic plasmacytoid dendritic cell neoplasm mimicking systemic lymphoma: a multidisciplinary diagnostic challenge.Frontiers in medicine · 2026Article
- Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease.Biology · 2025Review
- Improving CAR T cell therapy against malignancies through gene knock-down/out strategies: a systematic review.Cancer cell international · 2025Review
- Review
- Article
- CAR-T cell therapy for cancer: current challenges and future directions.Signal transduction and targeted therapy · 2025Review
- BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism.Cell death discovery · 2025Article
- Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm.International journal of molecular sciences · 2025Review
- Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.Journal of personalized medicine · 2025Review
- Review
- Case Report: Early diagnostic precision matters: navigating therapeutic uncertainty in pediatric BPDCN illustrated by misdiagnosis sequelae and fleeting CAR-T response.Frontiers in pediatrics · 2025Article
- The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia.HemaSphere · 2025Article
- BH3 Mimetics Augment Cytotoxic T Cell Killing of Acute Myeloid Leukemia via Mitochondrial Apoptotic Mechanism.Research square · 2024Article
- Ulcerating skin lesions from blastic plasmacytoid dendritic cell neoplasm responding to low-dose radiotherapy-a case report and literature review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Review
- Review
- Engineering immune-evasive allogeneic cellular immunotherapies.Nature reviews. Immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 4 institutions in 1 country.
Tianyu CaiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.ORCID 0000-0002-5271-3235
Agnès GoubleCellectis SA, Paris, France.
Kathryn L BlackDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Anna SkwarskaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Ammar S NaqviDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-0625-666X
Deanne TaylorDepartment of Biomedical & Health Informatics, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-3302-4610
Ming ZhaoSchool of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qi YuanDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9718-7593
Mayumi SugitaDepartment of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-8510-7154
Qi ZhangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.ORCID 0000-0002-7918-8952
Roman GalettoCellectis SA, Paris, France.
Stéphanie FilipeCellectis SA, Paris, France.
Antonio CavazosDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Lina HanDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Vinitha KuruvillaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Helen MaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Connie WengDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Chang-Gong LiuDepartment of Experimental Therapeutics, The University of MD Anderson Cancer Center, Houston, TX, USA.
Xiuping LiuDepartment of Experimental Therapeutics, The University of MD Anderson Cancer Center, Houston, TX, USA.
Sergej KonoplevDepartment of Hematopathology, The University of MD Anderson Cancer Center, Houston, TX, USA.
Jun GuSchool of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8225-9651
Guilin TangDepartment of Hematopathology, The University of MD Anderson Cancer Center, Houston, TX, USA.
Xiaoping SuDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gheath Al-AtrashDepartment of Stem Cell Transplantation and Cellular Therapy, The University of MD Anderson Cancer Center, Houston, TX, USA.
Stefan CiureaDepartment of Stem Cell Transplantation and Cellular Therapy, The University of MD Anderson Cancer Center, Houston, TX, USA.
Sattva S NeelapuDepartment of Lymphoma and Myeloma, The University of MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1045-4914
Andrew A LaneDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-7380-0226
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.ORCID 0000-0002-1908-3307
Monica L GuzmanDepartment of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9262-8246
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.
Julianne SmithCellectis SA, Paris, France.
Andrei Thomas-TikhonenkoDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA. mkonople@mdanderson.org.ORCID 0000-0002-9347-2212
The University of Texas MD Anderson Cancer Center · USChildren's Hospital of Philadelphia · USCornell University · USDana-Farber Cancer Institute · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUniversity of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7MCassette exons in neoplastic pro-B-cells: implications for immunotherapyU01CA232563 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI BARASH, YOSEPH, THOMAS-TIKHONENKO, ANDREI · 2018 to 2022
$3.5MTargeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)R37CA225191 · NCI · DANA-FARBER CANCER INST · PI LANE, ANDREW A · 2018 to 2024
$3.0MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632NCI NIH HHS R37 CA225191NCI NIH HHS U01 CA232563
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially expressed on the surface of BPDCN cells, it has emerged as an attractive therapeutic target. UCART123 is an investigational product consisting of allogeneic T cells expressing an anti-CD123 chimeric antigen receptor (CAR), edited with TALEN
Indexed as
Hematologic NeoplasmsHematopoietic Stem Cell TransplantationMyeloproliferative DisordersSkin NeoplasmsAcute DiseaseAnimalsDendritic CellsHumansInterleukin-3 Receptor alpha SubunitMiceInterleukin-3 Receptor alpha Subunit
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.